Department of Nuclear Medicine, Southwest Hospital, Third Military Medical University, Chongqing, China.
PLoS One. 2013;8(1):e54264. doi: 10.1371/journal.pone.0054264. Epub 2013 Jan 24.
BACKGROUND/PURPOSE: The VPAC1 receptor, a member of the vasoactive intestinal peptide receptors (VIPRs), is overexpressed in the most frequently occurring malignant tumors and plays a major role in the progression and angiogenesis of a number of malignancies. Recently, phage display has become widely used for many applications, including ligand generation for targeted imaging, drug delivery and therapy. In this work, we developed a panning procedure using a phage display peptide library to select a peptide that specifically binds to the VPAC1 receptor to develop a novel targeted probe for molecular imaging and therapy.
CHO-K1 cells stably expressing VPAC1 receptors (CHO-K1/VPAC1 cells) were used to select a VPAC1-binding peptide from a 12-mer phage peptide library. DNA sequencing and homologous analysis of the randomly selected phage clones were performed. A cellular ELISA was used to determine the most selectively binding peptide for further investigation. Binding specificity to the VPAC1 receptor was analyzed by competitive inhibition ELISA and flow cytometry. The binding ability of the selected peptide to CHO-K1/VPAC1 cells and colorectal cancer (CRC) cell lines was confirmed using fluorescence microscopy and flow cytometry.
A significant enrichment of phages that specifically bound to CHO-K1/VPAC1 cells was obtained after four rounds of panning. Of the selected phage clones, 16 out of 60 shared the same peptide sequence, GFRFGALHEYNS, which we termed the VP2 peptide. VP2 and vasoactive intestinal peptide (VIP) competitively bound to the VPAC1 receptor. More importantly, we confirmed that VP2 specifically bound to CHO-K1/VPAC1 cells and several CRC cell lines.
Our results demonstrate that the VP2 peptide could specifically bind to VPAC1 receptor and several CRC cell lines. And VP2 peptide may be a potential candidate to be developed as a useful diagnostic molecular imaging probe for early detection of CRC.
背景/目的:血管活性肠肽受体(VIPRs)成员 VPAC1 受体在最常见的恶性肿瘤中过度表达,在多种恶性肿瘤的进展和血管生成中发挥重要作用。最近,噬菌体展示技术已广泛应用于许多领域,包括配体生成、靶向成像、药物输送和治疗等。在这项工作中,我们使用噬菌体展示肽文库开发了一种淘选程序,以筛选出一种特异性结合 VPAC1 受体的肽,从而开发出一种新型的靶向探针,用于分子成像和治疗。
CHO-K1 细胞稳定表达 VPAC1 受体(CHO-K1/VPAC1 细胞),用于从 12 肽噬菌体肽文库中筛选出特异性结合 VPAC1 受体的肽。对随机选择的噬菌体克隆进行 DNA 测序和同源性分析。细胞 ELISA 用于确定进一步研究的最具选择性结合肽。通过竞争抑制 ELISA 和流式细胞术分析结合 VPAC1 受体的特异性。通过荧光显微镜和流式细胞术证实所选肽与 CHO-K1/VPAC1 细胞和结直肠癌(CRC)细胞系的结合能力。
经过四轮淘选,获得了对 CHO-K1/VPAC1 细胞具有特异性结合的噬菌体的显著富集。在 60 个所选噬菌体克隆中,有 16 个克隆共享相同的肽序列 GFRFGALHEYNS,我们将其命名为 VP2 肽。VP2 和血管活性肠肽(VIP)竞争性结合 VPAC1 受体。更重要的是,我们证实 VP2 特异性结合 CHO-K1/VPAC1 细胞和几种 CRC 细胞系。
我们的结果表明,VP2 肽可以特异性结合 VPAC1 受体和几种 CRC 细胞系。VP2 肽可能是开发为 CRC 早期检测有用的诊断分子成像探针的潜在候选物。